Traws Pharma, Inc.(TRAW) - 2024 Q4 - Annual Results

Exhibit 99.1 Traws Pharma Reports Full Year 2024 Results and Business Highlights Tivoxavir marboxil's potential as a single dose therapeutic agent for bird flu supported by significant antiviral activity in three well accepted animal models and positive Phase 1 data Ongoing FDA interaction to align on path forward for tivoxavir marboxil, including potential for accelerated approval utilizing the "Animal Rule" Cash Runway to support planned operations into Q1 2026 Investor Update call today, March 31, 2025 a ...